1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > European Physicians’ Biosimilar Views: A Primer

European Physicians’ Biosimilar Views: A Primer

  • March 2014
  • -
  • Industry Standard Research
  • -
  • 40 pages

In February 2014, Alvogen announced the launch of Inflectra (infliximab) into Central and Eastern Europe. Inflectra is a biosimilar medicine to the reference medicinal product, Remicade, and is the first monoclonal antibody to be approved through the European Medicines Agency (EMA) biosimilars regulatory pathway. Remicade recorded European sales of over USD 2 billion in 2012.

So the biosimilar approvals are coming, but will physicians prescribe them? To find out, ISR asked 348 board-certified physicians across Spain, Italy, France, and Germany what they thought about prescribing biosimilar products.

What you will learn in this report:

- European physicians’ familiarity with biologic and biosimilar medicines
- Physician attitudes toward clinical development requirements for biosimilar medicines
- Physician views on pharmacy-level substitutions
- Importance of medication cost when prescribing
- Impact biosimilar pricing has on prescribing recommendations
- Physician concern with safety and efficacy of biosimilar products
- Current and future prescribing behavior for biosimilar medicines

Methodologies:
348 European physicians were surveyed for this report on the biosimilar landscape in France (N=87), Spain (N=87), Germany (N=87), and Italy (N=87).

To qualify to take this survey, physicians had to pass several screening criteria:

- Had to currently prescribe medications to patients
- Had to be board certified in one of the following therapeutic areas:

- Dermatology
- Endocrinology
- Gastrointestinal
- Hematology oncology
- Nephrology
- Neurology
- Oncology
- Rheumatology

Table Of Contents

European Physicians’ Biosimilar Views: A Primer
Table of Contents

Copyright and Usage Guidelines 3
Introduction 4
Methodology 5
Analysis note 6
Definition of biosimilars 7
Demographics and Qualifications 8
Practice environment description 8
Tenure in healthcare 10
Practice area/ specialty 11
Weekly patient volume 13
Biologic prescribing 14
Executive Summary 15
Familiarity 23
Biologic medicines 24
Biosimilar medicines 25
Regulatory 26
Clinical development requirements 27
Pharmacy-level substitution - agree/disagree 28
Past, present, and future influence of government payers in prescribing options 29
Economics 30
Importance of medication cost on prescribing 31
Biosimilar pricing and the impact on prescribing recommendations 32
Biosimilar prescribing behavior 33
Bigger biosimilar concern - safety or efficacy 34
Likelihood to prescribe a biosimilar 35
Ability to prescribe an original product when a biosimilar exists 36
Current level of flexibility in prescribing biologic/ biosimilar products 37
Future level of flexibility in prescribing biologic/ biosimilar products 38
Impact of prescribing based on manufacturer 39
About Industry Standard Research 40

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Biosimilars Market by Product, Manufacturing, Application - Global Forecast to 2021

Biosimilars Market by Product, Manufacturing, Application - Global Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CM0) & Application ...

Global Biosimilar Drugs Market Analysis 2016 - Forecast to 2022

Global Biosimilar Drugs Market Analysis 2016 - Forecast to 2022

  • $ 4550
  • Industry report
  • January 2017
  • by Hoovers Research

Hoovers Research analysis is one of the most accurate studies performed using the combinational analytical tools. The report contains up to date financial data derived from varied research sources to present ...

Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022

Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022

  • $ 1500
  • Industry report
  • February 2017
  • by Kuick Research

“Global Biosimilar Insulin Market Opportunity & Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.